Molecular mechanism of action of pharmacoperone rescue of misrouted GPCR mutants: The GnRH receptor

Jo Ann Janovick, Akshay Patny, Ralph Mosley, Mark T. Goulet, Michael D. Altman, Thomas S. Rush, Anda Cornea, P. Michael Conn

    Research output: Contribution to journalArticle

    34 Citations (Scopus)

    Abstract

    The human GnRH receptor (hGnRHR), a G protein-coupled receptor, is a useful model for studying pharmacological chaperones (pharmacoperones), drugs that rescue misfolded and misrouted protein mutants and restore them to function. This technique forms the basis of a therapeutic approach of rescuing mutants associated with human disease and restoring them to function. The present study relies on computational modeling, followed by site-directed mutagenesis, assessment of ligand binding, effector activation, and confocal microscopy. Our results show that two different chemical classes of pharmacoperones act to stabilize hGnRHR mutants by bridging residues D 98 and K 121. This ligand-mediated bridge serves as a surrogate for a naturally occurring and highly conserved salt bridge (E 90-K 121) that stabilizes the relation between transmembranes 2 and 3, which is required for passage of the receptor through the cellular quality control system and to the plasma membrane. Our model was used to reveal important pharmacophoric features, and then identify a novel chemical ligand, which was able to rescue a D 98 mutant of the hGnRHR that could not be rescued as effectively by previously known pharmacoperones.

    Original languageEnglish (US)
    Pages (from-to)157-168
    Number of pages12
    JournalMolecular Endocrinology
    Volume23
    Issue number2
    DOIs
    StatePublished - Feb 2009

    Fingerprint

    Molecular Mechanisms of Pharmacological Action
    LHRH Receptors
    Pharmacology
    Ligands
    Drug Repositioning
    Mutant Proteins
    G-Protein-Coupled Receptors
    Site-Directed Mutagenesis
    Confocal Microscopy
    Quality Control
    Salts
    Cell Membrane

    ASJC Scopus subject areas

    • Molecular Biology
    • Endocrinology

    Cite this

    Janovick, J. A., Patny, A., Mosley, R., Goulet, M. T., Altman, M. D., Rush, T. S., ... Michael Conn, P. (2009). Molecular mechanism of action of pharmacoperone rescue of misrouted GPCR mutants: The GnRH receptor. Molecular Endocrinology, 23(2), 157-168. https://doi.org/10.1210/me.2008-0384

    Molecular mechanism of action of pharmacoperone rescue of misrouted GPCR mutants : The GnRH receptor. / Janovick, Jo Ann; Patny, Akshay; Mosley, Ralph; Goulet, Mark T.; Altman, Michael D.; Rush, Thomas S.; Cornea, Anda; Michael Conn, P.

    In: Molecular Endocrinology, Vol. 23, No. 2, 02.2009, p. 157-168.

    Research output: Contribution to journalArticle

    Janovick, JA, Patny, A, Mosley, R, Goulet, MT, Altman, MD, Rush, TS, Cornea, A & Michael Conn, P 2009, 'Molecular mechanism of action of pharmacoperone rescue of misrouted GPCR mutants: The GnRH receptor', Molecular Endocrinology, vol. 23, no. 2, pp. 157-168. https://doi.org/10.1210/me.2008-0384
    Janovick, Jo Ann ; Patny, Akshay ; Mosley, Ralph ; Goulet, Mark T. ; Altman, Michael D. ; Rush, Thomas S. ; Cornea, Anda ; Michael Conn, P. / Molecular mechanism of action of pharmacoperone rescue of misrouted GPCR mutants : The GnRH receptor. In: Molecular Endocrinology. 2009 ; Vol. 23, No. 2. pp. 157-168.
    @article{4e71ddb94da541a285373ddf97ef6aec,
    title = "Molecular mechanism of action of pharmacoperone rescue of misrouted GPCR mutants: The GnRH receptor",
    abstract = "The human GnRH receptor (hGnRHR), a G protein-coupled receptor, is a useful model for studying pharmacological chaperones (pharmacoperones), drugs that rescue misfolded and misrouted protein mutants and restore them to function. This technique forms the basis of a therapeutic approach of rescuing mutants associated with human disease and restoring them to function. The present study relies on computational modeling, followed by site-directed mutagenesis, assessment of ligand binding, effector activation, and confocal microscopy. Our results show that two different chemical classes of pharmacoperones act to stabilize hGnRHR mutants by bridging residues D 98 and K 121. This ligand-mediated bridge serves as a surrogate for a naturally occurring and highly conserved salt bridge (E 90-K 121) that stabilizes the relation between transmembranes 2 and 3, which is required for passage of the receptor through the cellular quality control system and to the plasma membrane. Our model was used to reveal important pharmacophoric features, and then identify a novel chemical ligand, which was able to rescue a D 98 mutant of the hGnRHR that could not be rescued as effectively by previously known pharmacoperones.",
    author = "Janovick, {Jo Ann} and Akshay Patny and Ralph Mosley and Goulet, {Mark T.} and Altman, {Michael D.} and Rush, {Thomas S.} and Anda Cornea and {Michael Conn}, P.",
    year = "2009",
    month = "2",
    doi = "10.1210/me.2008-0384",
    language = "English (US)",
    volume = "23",
    pages = "157--168",
    journal = "Molecular Endocrinology",
    issn = "0888-8809",
    publisher = "The Endocrine Society",
    number = "2",

    }

    TY - JOUR

    T1 - Molecular mechanism of action of pharmacoperone rescue of misrouted GPCR mutants

    T2 - The GnRH receptor

    AU - Janovick, Jo Ann

    AU - Patny, Akshay

    AU - Mosley, Ralph

    AU - Goulet, Mark T.

    AU - Altman, Michael D.

    AU - Rush, Thomas S.

    AU - Cornea, Anda

    AU - Michael Conn, P.

    PY - 2009/2

    Y1 - 2009/2

    N2 - The human GnRH receptor (hGnRHR), a G protein-coupled receptor, is a useful model for studying pharmacological chaperones (pharmacoperones), drugs that rescue misfolded and misrouted protein mutants and restore them to function. This technique forms the basis of a therapeutic approach of rescuing mutants associated with human disease and restoring them to function. The present study relies on computational modeling, followed by site-directed mutagenesis, assessment of ligand binding, effector activation, and confocal microscopy. Our results show that two different chemical classes of pharmacoperones act to stabilize hGnRHR mutants by bridging residues D 98 and K 121. This ligand-mediated bridge serves as a surrogate for a naturally occurring and highly conserved salt bridge (E 90-K 121) that stabilizes the relation between transmembranes 2 and 3, which is required for passage of the receptor through the cellular quality control system and to the plasma membrane. Our model was used to reveal important pharmacophoric features, and then identify a novel chemical ligand, which was able to rescue a D 98 mutant of the hGnRHR that could not be rescued as effectively by previously known pharmacoperones.

    AB - The human GnRH receptor (hGnRHR), a G protein-coupled receptor, is a useful model for studying pharmacological chaperones (pharmacoperones), drugs that rescue misfolded and misrouted protein mutants and restore them to function. This technique forms the basis of a therapeutic approach of rescuing mutants associated with human disease and restoring them to function. The present study relies on computational modeling, followed by site-directed mutagenesis, assessment of ligand binding, effector activation, and confocal microscopy. Our results show that two different chemical classes of pharmacoperones act to stabilize hGnRHR mutants by bridging residues D 98 and K 121. This ligand-mediated bridge serves as a surrogate for a naturally occurring and highly conserved salt bridge (E 90-K 121) that stabilizes the relation between transmembranes 2 and 3, which is required for passage of the receptor through the cellular quality control system and to the plasma membrane. Our model was used to reveal important pharmacophoric features, and then identify a novel chemical ligand, which was able to rescue a D 98 mutant of the hGnRHR that could not be rescued as effectively by previously known pharmacoperones.

    UR - http://www.scopus.com/inward/record.url?scp=58849083853&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=58849083853&partnerID=8YFLogxK

    U2 - 10.1210/me.2008-0384

    DO - 10.1210/me.2008-0384

    M3 - Article

    C2 - 19095769

    AN - SCOPUS:58849083853

    VL - 23

    SP - 157

    EP - 168

    JO - Molecular Endocrinology

    JF - Molecular Endocrinology

    SN - 0888-8809

    IS - 2

    ER -